These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 20222806

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Integrated strategy for the production of therapeutic retroviral vectors.
    Carrondo M, Panet A, Wirth D, Coroadinha AS, Cruz P, Falk H, Schucht R, Dupont F, Geny-Fiamma C, Merten OW, Hauser H.
    Hum Gene Ther; 2011 Mar; 22(3):370-9. PubMed ID: 21043806
    [Abstract] [Full Text] [Related]

  • 6. Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration.
    Bandeira VS, Tomás HA, Alici E, Carrondo MJ, Coroadinha AS.
    Hum Gene Ther Methods; 2017 Apr; 28(2):78-90. PubMed ID: 28301970
    [Abstract] [Full Text] [Related]

  • 7. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [Abstract] [Full Text] [Related]

  • 8. Impact of retroviral vector components stoichiometry on packaging cell lines: effects on productivity and vector quality.
    Carrondo MJ, Merten OW, Haury M, Alves PM, Coroadinha AS.
    Hum Gene Ther; 2008 Feb; 19(2):199-210. PubMed ID: 18092921
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.
    Byun J, Kim SH, Kim JM, Yu SS, Robbins PD, Yim J, Kim S.
    Gene Ther; 1996 Sep; 3(9):780-8. PubMed ID: 8875226
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
    Tabotta W, Klein D, Hohenadl C, Salmons B, Günzburg WH.
    J Gene Med; 2001 Sep; 3(5):418-26. PubMed ID: 11601755
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience.
    Reeves L, Smucker P, Cornetta K.
    Hum Gene Ther; 2000 Oct 10; 11(15):2093-103. PubMed ID: 11044911
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improvement of retroviral packaging cell lines by introducing the polyomavirus early region.
    Yoshimatsu T, Tamura M, Kuriyama S, Ikenaka K.
    Hum Gene Ther; 1998 Jan 20; 9(2):161-72. PubMed ID: 9472776
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.